814918-95-1

Basic information

• Product Name: 5-bromo-4-chlorothieno[2,3-d]pyrimidine
• Synonyms: 5-bromo-4-chlorothieno[2,3-d]pyrimidine;5-BroMo-4-chlorothieno[2,...;Thieno[2,3-d]pyrimidine, 5-bromo-4-chloro-
• CAS NO: 814918-95-1
• Molecular Formula: C₆H₂BrClN₂S
• Molecular Weight: 249.51
• Product Categories: pyrimidine;Heterocycle-Pyrimidine series
• Mol File: 814918-95-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 345.453 °C at 760 mmHg
• Flash Point: 162.724 °C
• Appearance: /
• Density: 1.955 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.736
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -0.31±0.40(Predicted)
• CAS DataBase Reference: 5-bromo-4-chlorothieno[2,3-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-4-chlorothieno[2,3-d]pyrimidine(814918-95-1)
• EPA Substance Registry System: 5-bromo-4-chlorothieno[2,3-d]pyrimidine(814918-95-1)

Safety Data

• Hazardous Substances Data: 814918-95-1(Hazardous Substances Data)

Usage

General Description

5-bromo-4-chlorothieno[2,3-d]pyrimidine is a widely used chemical compound in the field of scientific research, predominantly in areas such as biochemistry and medicine. It is an organic compound referring to a specific type of thienopyrimidine, making it a heterocyclic compound. Its specific structure consists of a pyrimidine ring fused with a thiophene ring, with bromine and chlorine substituents occupying specific positions on the molecule's structure. These specific characteristics give it unique chemical properties, making it useful in various fields of research. However, detailed usage or properties of the compound are generally related to the particular research context, as detailed information on its toxicity, health effects and environmental impact is not readily available.

InChI:InChI=1/C6H2BrClN2S/c7-3-1-11-6-4(3)5(8)9-2-10-6/h1-2H

Upstream product

• 14080-50-3 thieno[2,3-d]pyrimidin-4(1H)-one 
• 56844-40-7 6-bromothieno[2,3-d]pyrimidin-4(3H)-one 
• 14080-50-3 thieno[2,3-d]pyrimidin-4(3H)one 
• 1239460-82-2 5,6-dibromothieno[2,3-d]pyrimidin-4(3H)-one 
• 4651-82-5 2-amino-3-cyanothiophene 
• 56844-12-3 6-bromo-4-chlorothieno[2,3-d]pyrimidine 

Downstream Products

• 1239460-84-4 5-bromo-4-hydrazinylthieno[2,3-d]pyrimidine 
• 1370338-71-8 4-chloro-5-(3-(methylsulfonyl)phenyl)thieno[2,3-d]pyrimidine 
• 1370338-31-0 2-methyl-5-(5-(3-(methylsulfonyl)phenyl)thieno[2,3-d]pyrimidin-4-ylthio)-1,3,4-oxadiazole 
• 1222765-97-0 4-((1-methyl-1H-tetrazol-5-yl)thio)-5-(3-(methylsulfonyl)phenyl)thieno[2,3-d]pyrimidine 
• 1571111-36-8 6-(4-aminothieno[2,3-d]pyrimidin-5-yl)-N-phenyl-1-naphthalenecarboxamide 
• 1388892-85-0 tert-butyl {(1r,4r)-4-[(5-bromothieno[2,3-d]pyrimidin-4-yl)oxy]cyclohexyl}(methyl)carbamate 
• 1388892-49-6 4-N-[5-(1-benzofuran-2-yl)thieno[2,3-d]pyrimidin-4-yl]-1-N,1-N-dimethylcyclohexane-1,4-diamine 
• 1388892-51-0 4-N-[5-bromothieno[2,3-d]pyrimidin-4-yl]-1-N,1-N-dimethylcyclohexane-1,4-diamine 
• 1388892-88-3 tert-butyl ((1r,4r)-4-{[5-(benzofuran-2-yl)thieno[2,3-d]pyrimidin-4-yl]oxy}cyclohexyl)(methyl)carbamate 
• 1388892-83-8 4-{[5-(1-benzofuran-2-yl)thieno[2,3-d]pyrimidin-4-yl]oxy}-N,N-dimethylcyclohexan-1-amine 
• 1337531-56-2 5-{1-[(3-methylphenyl)acetyl]-2,3-dihydro-1H-indol-5-yl}thieno[2,3-d]pyrimidin-4-amine 
• 1337532-92-9 5-bromo-thieno[2,3-d]pyrimidin-4-ylamine 
• 1337531-23-3 5-{1-[(2,5-difluorophenyl)acetyl]-2,3-dihydro-1H-indol-5-yl} thieno[2,3-d]pyrimidin-4-amine 
• 885229-24-3 5-Bromo-N-[1-(4-methoxyphenyl)ethyl]thieno[2,3-d]pyrimidin-4-amine 

Relevant articles and documents

IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK

The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING OR PREVENTING NEURODEGENERATIVE DISEASES OR DISORDERS

Disclosed are compounds of the formula (I): wherein R1, R2, X, Y, and Z as described herein, or pharmaceutically acceptable salts thereof, for use in treating or preventing neurodegenerative diseases and disorders such as Huntington'

INHIBITORS OF JUN N-TERMINAL KINASE

The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.